CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ - PubMed (original) (raw)
CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
S Radoja et al. J Immunol. 2001.
Abstract
Induction of Fas-mediated activation-induced cell death in antitumor T cells has been hypothesized to permit tumor escape from immune destruction. Several laboratories have proposed that expression of Fas ligand (L) by tumor is the basis for this form of T cell tolerance. In this study, we characterized murine tumor-infiltrating lymphocytes (TIL) for activation status, cell cycle status, level of apoptosis, cytokine secretion, and proliferative capacity. TILs express multiple activation markers (circa CD69, CD95L, CD122, and LFA-1) and contain IL-2 and IFN-gamma mRNAs, but are neither cycling nor apoptotic in situ. In addition, TIL are dramatically suppressed in proliferative response and do not secrete IL-2 and IFN-gamma. However, upon purification and activation in vitro, TIL secrete high levels of IL-2 and IFN-gamma, enter S phase, and then die by Fas-mediated apoptosis. Activation by injection of anti-TCR Ab or IL-2 into tumor-bearing mice induced TIL entrance into S phase preceding apoptosis, showing that TIL have functional TCR-mediated signal transduction in situ. Our data demonstrate that TIL, not tumor, express both Fas and FasL, are arrested in G(1), do not secrete cytokine in situ, and, upon activation in vitro and in vivo, rapidly die by activation-induced cell death.
Similar articles
- Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Zaks TZ, et al. J Immunol. 1999 Mar 15;162(6):3273-9. J Immunol. 1999. PMID: 10092779 Free PMC article. - Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Reichert TE, et al. Clin Cancer Res. 2002 Oct;8(10):3137-45. Clin Cancer Res. 2002. PMID: 12374681 - Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.
Koneru M, Schaer D, Monu N, Ayala A, Frey AB. Koneru M, et al. J Immunol. 2005 Feb 15;174(4):1830-40. doi: 10.4049/jimmunol.174.4.1830. J Immunol. 2005. PMID: 15699109 - Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. O'Connell J, et al. Dis Esophagus. 1999;12(2):83-9. doi: 10.1046/j.1442-2050.1999.00033.x. Dis Esophagus. 1999. PMID: 10466039 Review. - Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
Zhu J, Petit PF, Van den Eynde BJ. Zhu J, et al. Cancer Immunol Immunother. 2019 May;68(5):835-847. doi: 10.1007/s00262-018-2269-y. Epub 2018 Nov 7. Cancer Immunol Immunother. 2019. PMID: 30406374 Free PMC article. Review.
Cited by
- CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?
Turner CN, Mullins GN, Hoyer KK. Turner CN, et al. Front Med (Lausanne). 2022 Oct 13;9:1034764. doi: 10.3389/fmed.2022.1034764. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36314014 Free PMC article. Review. - Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory.
Leleux JA, Albershardt TC, Reeves R, James R, Krull J, Parsons AJ, Ter Meulen J, Berglund P. Leleux JA, et al. PLoS One. 2021 Dec 2;16(12):e0259301. doi: 10.1371/journal.pone.0259301. eCollection 2021. PLoS One. 2021. PMID: 34855754 Free PMC article. - Cellular and Molecular Mechanisms of CD8+ T Cell Differentiation, Dysfunction and Exhaustion.
Verdon DJ, Mulazzani M, Jenkins MR. Verdon DJ, et al. Int J Mol Sci. 2020 Oct 5;21(19):7357. doi: 10.3390/ijms21197357. Int J Mol Sci. 2020. PMID: 33027962 Free PMC article. Review. - Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.
Walsh SR, Simovic B, Chen L, Bastin D, Nguyen A, Stephenson K, Mandur TS, Bramson JL, Lichty BD, Wan Y. Walsh SR, et al. J Clin Invest. 2019 Dec 2;129(12):5400-5410. doi: 10.1172/JCI126199. J Clin Invest. 2019. PMID: 31682239 Free PMC article. - Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.
Waugh KA, Leach SM, Moore BL, Bruno TC, Buhrman JD, Slansky JE. Waugh KA, et al. J Immunol. 2016 Aug 15;197(4):1477-88. doi: 10.4049/jimmunol.1600589. Epub 2016 Jul 1. J Immunol. 2016. PMID: 27371726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous